Furthermore, in contrast to IL‐23 blockers, Tyk2 inhibition with deucravacitinib failed to show efficacy in UC despite good efficacy for both psoriasis and PsA,21 although JAK1 inhibition that blocks the common γ chain needed for T cell proliferation and activation is license in IBD. Here, IL23A is linked to inflammatory bowel disease.